Durability and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with moderate to severe inflammatory bowel disease.|https://dx.doi.org/10.5217/ir.2023.00100
Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015-2019: The RECUR England study.|https://dx.doi.org/10.1016/j.ijid.2024.01.002
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease.|https://dx.doi.org/10.1016/j.molmed.2023.12.005
Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study.|https://dx.doi.org/10.1093/cid/ciae007
Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study.|https://dx.doi.org/10.1093/ofid/ofad622
Unlocking Bevacizumab's Potential: rCBV(max) as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients.|https://dx.doi.org/10.3390/cancers16010161
Clostridioides difficile Infection in Hospitalized Patients-A Retrospective Epidemiological Study.|https://dx.doi.org/10.3390/healthcare12010076
Generalisability of predictive models for Clostridioides difficile infection, severity, and recurrence at an urban safety-net hospital.|https://dx.doi.org/10.1016/j.jhin.2024.01.001
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.|https://dx.doi.org/10.1007/s40121-023-00907-w
Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence.|https://dx.doi.org/10.1007/s10096-024-04762-6
Efficacy of noncarbapenem therapy for the treatment of ceftriaxone-resistant Enterobacterales outside the urinary tract.|https://dx.doi.org/10.1017/ash.2023.137
Pyrin Inflammasome Activation Defines Colchicine-Responsive SURF Patients from FMF and Other Recurrent Fevers.|https://dx.doi.org/10.1007/s10875-023-01649-7
Loratadine is an anti-inflammatory agent against C. difficile toxin B.|https://dx.doi.org/10.1093/infdis/jiae021
Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.|https://dx.doi.org/10.1371/journal.pone.0295627
Patients With First-Time or Recurrent Patellar Dislocation Have a Similar High Rate and Extent of Articular Cartilage Injury Observed on Magnetic Resonance Imaging.|https://dx.doi.org/10.1016/j.asmr.2023.100849
Use of electronic health record data to identify hospital-associated Clostridioides difficile infections: a validation study.|https://dx.doi.org/10.1101/2024.01.10.24301118
Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review.|https://dx.doi.org/10.7759/cureus.51004
The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.|https://dx.doi.org/10.1093/jac/dkae012
Gut Microbiota-Gut Metabolites and Clostridioides difficile Infection: Approaching Sustainable Solutions for Therapy.|https://dx.doi.org/10.3390/metabo14010074
Potential underreporting of treated patients using a Clostridioides difficile testing algorithm that screens with a nucleic acid amplification test.|https://dx.doi.org/10.1017/ice.2023.262
Anti-S-layer monoclonal antibodies impact Clostridioides difficile physiology.|https://dx.doi.org/10.1080/19490976.2023.2301147
Impact of oral vancomycin treatment duration on rate of Clostridioides difficile recurrence in patients requiring concurrent systemic antibiotics.|https://dx.doi.org/10.1017/ice.2024.4
Antimicrobial Resistance of Clostridioides difficile in Children from a Tertiary Pediatric Hospital in Shanghai, China.|https://dx.doi.org/10.2147/IDR.S441312
Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices.|https://dx.doi.org/10.1016/j.jhep.2024.01.018
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.|https://dx.doi.org/10.1093/cid/ciad792
Concomitant Lymphocytic Colitis With Recurrent Clostridium difficile Infection.|https://dx.doi.org/10.7759/cureus.51606
Characterizing the flavodoxin landscape in Clostridioides difficile.|https://dx.doi.org/10.1128/spectrum.01895-23
